ClinicalTrials.gg
Status unknownNCT03707561Updated Oct 25, 2018

RUS-registry of PH

An observational study in Pulmonary Hypertension, sponsored by Russian Cardiology Research and Production Center. Status unknown. Per ClinicalTrials.gov, last updated 2018-10-25.

Sponsored by Russian Cardiology Research and Production Center · Observational

How we know

The sponsor has not verified this record recently (last verified Oct 2018), so the status shown — last known as Enrolling by invitation — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
200
Sex
All
01

Study summary

Russian National Registry of Patients With Pulmonary Arterial Hypertension (PAH) and Chronic Thromboembolic Pulmonary Hypertension (CTEPH) is a multicenter, observational study of the clinical course and disease management of PAH and CTEPH patients. designed to gather demographic, clinical and prognostic data of routine medical care in prospective manner for newly initiated treatment since Jan 2016.

The internet-based registry (www.medibase.pro) fulfills high quality standards through several measures (planned minimum centre contribution of at least 10 patients per year, automated plausibility checks of data at entry, queries, monitoring with source data verification in >50% of participating centers).

All consecutive patients diagnosed with World Health Organization Pulmonary Hypertension Groups (WHO Group I) PAH according to specific hemodynamic criteria will be enrolled in participating centers after signing the informed consents. Participating patients will be followed for a minimum of five years from the time of enrollment.

It can be applied, among further purposes, for quality assurance: individual centers can confidentially compare their results with the combined outcome of the other centers. It is expected that the registry contributes to optimization of specific drug therapy for PAH and Pulmonary Hypertension (PH).

Read the detailed description

Russian National Registry of Patients With Pulmonary Arterial Hypertension and Chronic Thromboembolic Pulmonary Hypertension (RUS-registry of PH) will report current and comprehensive data on

  • Demographics, clinical course of incident PAH and CTEPH, the hemodynamic and functional status of patients
  • The main diagnostic approaches for the diagnosis of PAH and CTEPH.
  • Patient outcomes including survival, by subgroup, by treatment strategy and other factors
  • Clinical predictors of short-term and long-term clinical outcomes
  • Relationship between PAH- treatment medications and patient outcomes
  • Temporal trends in treatments and outcomes for newly diagnosed patients
  • The state of implementation of current PAH guidelines
  • To describe the status of operable or non-operable patients with PAH and CTEPH
  • To identify the most important prognostic indicators in patients with PH.
  • To study the basic principles of therapy of patients with PH.patients
  • To evolve research needs of the PAH community
02

Conditions studied

  • Pulmonary Hypertension
03

In context

Hypertension, Pulmonary

1,092 studies on the registry are indexed under Hypertension, Pulmonary; 243 are open to participants now.

This study's planned enrollment of 200 is above the median of 110 across 380 observational studies indexed under Hypertension, Pulmonary.

Browse Hypertension, Pulmonary studies →

Lead sponsor

Russian Cardiology Research and Production Center is the lead sponsor of 9 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

IPAH and heritable PAH, PAH associated with CHD, PAH associated with CTD, portoPH, PAH-HIV, operable CTEPH, non-operable CTEPH

Eligibility criteria

Inclusion Criteria:

Newly diagnosed PAH:

idiopathic form (IPAH) or PAH associated with connective tissue diseases (PAH-CTD), with congenital heart defects (PAH-CHD), with infection (PAH-HIV), or portopulmonary hypertension Newly diagnosed CTEPH- operable and non-operable

Documentation of the following hemodynamic parameters by right heart catheterization, performed at the time of study enrollment:

Mean pulmonary arterial pressure (mPAP) ≥ 25 mm Hg at rest Pulmonary wedge pressure \< 15 mm Hg Pulmonary vascular resistance (PVR) ≥ 240 dynes.sec.cm-5 (i.e., ≥ 3.0 Wood units) Signed Previously naïve patients with newly initiated therapy with endothelin receptor antagonists (ERA), phoshodiesterase-5 (PDE-5) inhibitors, soluble guanylate cyclase (sGC) stimulators or prostacyclins in mono- or combination therapy.

Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
200 participants (estimated)
Target follow-up
5 Years
Patient registry
Yes

Groups and cohorts

  • Group 1 - IPAH and heritable PAH

    Idiopathic pulmonary arterial hypertension (IPAH) and heritable PAH Diagnostic Test: Right Heart Catheterization (RHC)

    Diagnostic Test: Right Heart Catheterization (RHC)

  • Group 2- PAH associated with CHD

    Pulmonary arterial hypertension associated with congenital heart disease Diagnostic Test: Right Heart Catheterization (RHC)

    Diagnostic Test: Right Heart Catheterization (RHC)

  • Group 3- PAH associated with CTD

    Pulmonary Arterial Hypertension associated with Connective Tissue Diseases Diagnostic Test: Right Heart Catheterization (RHC)

    Diagnostic Test: Right Heart Catheterization (RHC)

  • Group 4- portoPH

    Portopulmonary hypertension

  • group 5- PAH-HIV

    Pulmonary arterial hypertension associated with HIV infection

  • group 6- operable CTEPH

    Operable chronic thromboembolic pulmonary hypertension Diagnostic Test: Right Heart Catheterization (RHC)

    Diagnostic Test: Right Heart Catheterization (RHC)

  • group 7- non-operable CTEPH

    Non operable chronic thromboembolic pulmonary hypertension Diagnostic Test: Right Heart Catheterization (RHC)

    Diagnostic Test: Right Heart Catheterization (RHC)

Interventions

  • Diagnostic testRight Heart Catheterization (RHC)

    RHC at the enrollment and every 12 months

06

What researchers measure

Primary outcomes

  1. RHC

    Change of pulmonary vascular resistance

    Time frame: 12 month

07

Study locations

No study locations are listed for this record.

08

References and documents

Publications

  • Chazova IE, Martynyuk TV. [Clinical guidelines for the diagnosis and treatment of chronic thromboembolic pulmonary hypertension (Part 1)]. Ter Arkh. 2016;88(9):90-101. doi: 10.17116/terarkh201688990-101. Russian. PubMed 27735920 ↗
  • Chazova IE, Martynyuk TV. [Clinical guidelines for the diagnosis and treatment of chronic thromboembolic pulmonary hypertension (Part 2)]. Ter Arkh. 2016;88(10):63-73. doi: 10.17116/terarkh201688663-73. Russian. PubMed 27801422 ↗
  • Chazova IE, Avdeev SN, Tsareva NA, Volkov AV, Martyniuk TV, Nakonechnikov SN. [Clinical guidelines for the diagnosis and treatment of pulmonary hypertension]. Ter Arkh. 2014;86(9):4-23. Russian. PubMed 25518501 ↗
  • Taran IN, Belevskaya AA, Saidova MA, Martynyuk TV, Chazova IE. Initial Riociguat Monotherapy and Transition from Sildenafil to Riociguat in Patients with Idiopathic Pulmonary Arterial Hypertension: Influence on Right Heart Remodeling and Right Ventricular-Pulmonary Arterial Coupling. Lung. 2018 Dec;196(6):745-753. doi: 10.1007/s00408-018-0160-4. Epub 2018 Sep 4. PubMed 30182153 ↗
  • Chazova IE, Arkhipova OA, Valieva ZS, Nakonechnikov SN, Martyniuk TV. [Pulmonary hypertension in Russia: the first results of the national register]. Ter Arkh. 2014;86(9):56-64. Russian. PubMed 25518507 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2016, a primary completion of Dec 2020 and a completion of Jan 2021. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 11, 2018
First posted
Oct 16, 2018
Start
Jan 2016
Primary completionEst.
Dec 2020
CompletionEst.
Jan 2021
Last update
Oct 25, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 25, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03707561
Lead sponsor
Russian Cardiology Research and Production Center
Collaborators
Scientific Research Institute of Rheumatology
Responsible party
Tamila V. Martynyuk, MD, PhD (Russian Cardiology Research and Production Center, Russian Cardiology Research and Production Center) — Principal investigator
First posted
Oct 16, 2018
Start date
Jan 2016
Primary completion
Dec 2020 (estimated)
Completion
Jan 2021 (estimated)
Last update
Oct 25, 2018

Study contacts

Tamila Martynyuk, MD, PhD
principal investigator · Russian Cardiology Research and Production Center
Irina Chazova, MD, PhD
study chair · Russian Cardiology Research and Production Center
Olga Arkhipova, PhD
study director · Russian Cardiology Research and Production Center
Alexander Volkov, MD, PhD.
study director · Institute of Rheumatology named after VA Nasonova, Moscow, Russia
Vera Lukyantchikova, MD, PhD
study director · Regional Clinical Hospital №1, Khabarovsk, Russia
Elena Vetrova, PhD
study director · Belgorod Regional Clinical Hospital, Belgorod, Russia
Elena Devitiyarova, MD, PhD
study director · Rostov Regional State CLINICAL HOSPITAL, Russia
Olga Korolkova, MD, PhD
study director · Department of Hospital Therapy of the Voronezh State Medical Academy. N. N. Burdenko, Voronezh, Russia
Olga Andreyeva
study director · State Healthcare Institution Regional Cardiology Dispensary, Ulyanovsk, Russia
Svetlana Martynenko
study director · Regional Budget Cardiology Dispensary, Astrakhan, Russia
Elena Milovanova, PhD
study director · District Cardiology Dispensary "Center for Diagnostic and Cardiovascular Surgery", Surgut, Russia
Anna Rogacheva
study director · State Future Health Care Institution "Primorskaya Regional Clinical Hospital № 1", Vladivostok, Russia
Svetlana Kharitonova
study director · State budgetary health care institution "Bryansk Regional Cardiology Dispensary", Bryansk, Russia
Elena Shutemova, MD, PhD
study director · IVANOVO STATE MEDICAL ACADEMY Department of Therapy and General Practice, Ivanovo, Russia

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Oct 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion